A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing

Altex

Volumn 29, Issue 1, 2012, Pages 5-91

  Basketter, David A ^a   Clewell, Harvey ^b   Kimber, Ian ^c   Rossi, Annamaria ^d   Blaauboer, Bas ^e   Burrier, Robert ^f   Daneshian, Mardas ^d   Eskes, Chantra ^g   Goldberg, Alan ^h   Hasiwa, Nina ^d   Hoffmann, Sebastian ⁱ   Jaworska, Joanna ^j   Knudsen, Thomas B ^k   Landsiedel, Robert ^l   Leist, Marcel ^d   Locke, Paul ^h   Maxwell, Gavin ^m   McKim, James ⁿ   McVey, Emily A ^o   Ouédraogo, Gladys ^p   Patlewicz, Grace ^q   Pelkonen, Olavi ^r   Roggen, Erwin ^s   Rovida, Costanza ^d   Ruhdel, Irmela ^t   Schwarz, Michael ^u   Schepky, Andreas ^v   Schoeters, Greet ^w   Skinner, Nigel ^x   Trentz, Kerstin ^y   Turner, Marian ^g   Vanparys, Philippe ^z   Yager, James ^aa   Zurlo, Joanne ^h   Hartung, Thomas ^g   more..

^a DABMEB Consultancy Ltd   (United Kingdom)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF KONSTANZ   (Germany)

^e UTRECHT UNIVERSITY   (Netherlands)

^f Stemina Biomarker Discovery   (United States)

^g SeCAM ^*

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ Seh Consulting + Services   (Germany)

^j PROCTER AND GAMBLE COMPANY   (United States)

^k U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^l BASF SE   (Germany)

^m UNILEVER RESEARCH   (United Kingdom)

ⁿ CeeTox   (United States)

^o Notox BV   (Netherlands)

^p L ORÉAL RECHERCHE   (France)

^q DUPONT COMPANY   (United States)

^r UNIVERSITY OF OULU   (Finland)

^s NOVOZYMES A S   (Denmark)

^t Animal Welfare Academy   (Germany)

^u UNIVERSITY OF TÜBINGEN   (Germany)

^v BEIERSDORF AG   (Germany)

^w FLEMISH INSTITUTE FOR TECHNOLOGICAL RESEARCH VITO   (Belgium)

^x AGILENT TECHNOLOGIES   (United States)

^y Bioservices   (Germany)

^z ALTOXICON BVBA   (Belgium)

^aa JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Allergic contact dermatitis; Alternative approaches; Carcinogenicity; Predictive testing; Repeated dose testing; Reproductive toxicity; Risk assessment; Skin sensitization; Toxicokinetics

Indexed keywords

COSMETIC; NANOPARTICLE; TOXIC SUBSTANCE;

ANIMAL TESTING ALTERNATIVE; ANIMAL WELFARE; CARCINOGENICITY; CELL THERAPY; EUROPE; HUMAN; MEDICAL LITERATURE; NONHUMAN; REPRODUCTIVE TOXICITY; REVIEW; SAFETY; SKIN SENSITIZATION; TOXICITY TESTING; TOXICOKINETICS; UNITED STATES;

EID: 84860807149     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (502)

1. Abadie-Viollon, C., Martin, H., Blanchard, N., et al. (2010). Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions. Toxicol In Vitro 24, 346-356.
2. Adler, S., Basketter, D., Creton, S., et al. (2011). Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch Toxicol 85, 367-485.
3. Aeby, P., Ashikaga, T., Bessou-Touya, S., et al. (2010). Identifying and characterizing chemical skin sensitizers without animal testing: Colipa's research and method development program. Toxicol In Vitro 24, 1465-1473.
4. Alden, C. L., Smith, P. F., Piper, C. E., et al. (1996). A critical appraisal of the value of the mouse cancer bioassay in safety assessment. Toxicol Pathol 24, 722-725.
5. Aldenberg, T. and Jaworska, J. (2010). Multiple test in silico Weight-of-Evidence for toxicological endpoints. In M. Cronin and J. Madden (eds.), In Silico Toxicology: Principles and applications. Cambridge: Royal Society of Chemistry.
6. Ameen, C., Strehl, R., Bjorquist, P., et al. (2008). Human embryonic stem cells: current technologies and emerging industrial applications. Crit Rev Oncol Hematol 65, 54-80.
7. Ames, B. N. and Gold, L. S. (1990). Chemical carcinogenesis: too many rodent carcinogens. Proc Natl Acad Sci U S A 87, 7772-7776.
8. Ames, B. N., Profet, M., and Gold, L. S. (1990). Nature's chemicals and synthetic chemicals: comparative toxicology. Proc Natl Acad Sci U S A 87, 7782-7786.
9. Ames, B. N. and Gold, L. S. (2000). Paracelsus to parascience: the environmental cancer distraction. Mutat Res 447, 3-13.
10. An, S., Kim, S., Huh, Y., et al. (2009). Expression of surface markers on the human monocytic leukaemia cell line, THP-1, as indicators for the sensitizing potential of chemicals. Contact Dermatitis 60, 185-192.
11. Andersen, M. E. (1991). Physiological modelling of organic compounds. Ann Occup Hyg 35, 309-321.
12. Andersen, M. E., Thomas, R. S., Gaido, K. W., et al. (2005). Dose-response modeling in reproductive toxicology in the systems biology era. Reprod Toxicol 19, 327-337.
13. st century: a vision and a strategy?". ALTEX 28, 175-182.
14. Anisimov, V. N., Ukraintseva, S. V., and Yashin, A. I. (2005). Cancer in rodents: does it tell us about cancer in humans? Nat Rev Cancer 5, 807-819.
15. Anonymous (2000). Scientific Frontiers in Developmental Toxicology and Risk Assessment. Committee on Developmental Toxicology, Board on Environmental Studies and Toxicology, Commission on Life Sciences, National Research Council. Vol. Washington, DC: National Academy Press. http://www.nap.edu/catalog/9871. html
16. Anthony, A., Caldwell, J., Hutt, A. J., et al. (1987). Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1′-hydroxyestragole. Food Chem Toxicol 25, 799-806.
17. Api, A. M., Basketter, D. A., Cadby, P. A., et al. (2008). Dermal sensitization quantitative risk assessment (QRA) for fragrance ingredients. Regul Toxicol Pharmacol 52, 3-23.
18. Arkusz, J., Stepnik, M., Sobala, W., et al. (2010). Prediction of the contact sensitizing potential of chemicals using analysis of gene expression changes in human THP-1 monocytes. Toxicol Lett 199, 51-59.
19. Ashby, J. and Tennant, R. W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257, 229-306.
20. Ashby, J. (1997). Cell transformation assays as predictors of carcinogenic potential. Toxicol Pathol 25, 334-335.
21. Ashikaga, T., Sakaguchi, H., Sono, S., et al. (2010). A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA). Altern Lab Anim 38, 275-284.
22. Asp, J., Steel, D., Jonsson, M., et al. (2010). Cardiomyocyte clusters derived from human embryonic stem cells share similarities with human heart tissue. J Mol Cell Biol 2, 276-283.
23. Augustine-Rauch, K., Zhang, C. X., and Panzica-Kelly, J. M. (2010). In vitro developmental toxicology assays: A review of the state of the science of rodent and zebrafish whole embryo culture and embryonic stem cell assays. Birth Defects Res C Embryo Today 90, 87-98.
24. Bailey, J., Knight, A., and Balcombe, J. (2005). The future of teratology research is in vitro. Biogenic Amines 97-145.
25. Balls, M. and Combes, R. (2005). Validation at a crossroads. Altern Lab Anim 33, 187.
26. Balls, M., Amcoff, P., Bremer, S., et al. (2006). The principles of weight of evidence validation of test methods and testing strategies. The report and recommendations of ECVAM workshop 58. Altern Lab Anim 34, 603-620.
27. Balls, M. and Clothier, R. (2010). A FRAME response to the Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects - 2010. Altern Lab Anim 38, 345-353.
28. Banas, A., Teratani, T., Yamamoto, Y., et al. (2007). Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 46, 219-228.
29. Barlow, S. and Schlatter, J. (2010). Risk assessment of carcinogens in food. Toxicol Appl Pharmacol 243, 180-190.
30. Barratt, M. D. (2000). Prediction of toxicity from chemical structure. Cell Biol Toxicol 16, 1-13.
31. Basketter, D. and Maxwell, G. (2007). In vitro approaches to the identification and characterization of skin sensitizers. Cutan Ocul Toxicol 26, 359-373.
32. Basketter, D. A., Gerberick, F., and Kimber, I. (2007). The local lymph node assay and the assessment of relative potency: status of validation. Contact Dermatitis 57, 70-75.
33. Basketter, D. A. (2008). Nonanimal alternatives for skin sensitization: a step forward? Toxicol Sci 102, 1-2.
34. Basketter, D. A. and Kimber, I. (2009). Updating the skin sensitization in vitro data assessment paradigm in 2009. J Appl Toxicol 29, 545-550.
35. Basketter, D. A. and Kimber, I. (2011). Predictive tests for irritants and allergens and their use in quantitative risk assessment. In J. D. Johansen, P. F. Frosch and J. Lepoittevin (eds.), Contact Dermatitis. Berlin: Springer.
36. Bauch, C., Kolle, S. N., Fabian, E., et al. (2011). Intralaboratory validation of four in vitro assays for the prediction of the skin sensitizing potential of chemicals. Toxicol In Vitro 25, 1162-1168.
37. Baylin, S. B. and Ohm, J. E. (2006). Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6, 107-116.
38. Benet, L. Z., Cummins, C. L., and Wu, C. Y. (2003). Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4, 393-398.
39. Benfenati, E., Benigni, R., Demarini, D. M., et al. (2009). Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27, 57-90.
40. Benford, D., Bolger, P. M., Carthew, P., et al. (2010). Application of the Margin of Exposure (MOE) approach to substances in food that are genotoxic and carcinogenic. Food Chem Toxicol 48, Suppl 1, S2-24.
41. Benigni, R. and Giuliani, A. (2003). Putting the Predictive Toxicology Challenge into perspective: reflections on the results. Bioinformatics 19, 1194-1200.
42. Benigni, R. (2004). Chemical structure of mutagens and carcinogens and the relationship with biological activity. J Exp Clin Cancer Res 23, 5-8.
43. Benigni, R. and Zito, R. (2004). The second National Toxicology Program comparative exercise on the prediction of rodent carcinogenicity: definitive results. Mutat Res 566, 49-63.
44. Benigni, R. and Bossa, C. (2006). Structure-activity models of chemical carcinogens: state of the art, and new directions. Ann Ist Super Sanita 42, 118-126.
45. Benigni, R., Bossa, C., Tcheremenskaia, O., et al. (2010). Alternatives to the carcinogenicity bioassay: in silico methods, and the in vitro and in vivo mutagenicity assays. Expert Opin Drug Metab Toxicol 6, 809-819.
46. Benigni, R. and Bossa, C. (2011). Alternative strategies for carcinogenicity assessment: an efficient and simplified approach based on in vitro mutagenicity and cell transformation assays. Mutagenesis 26, 455-460.
47. Bernstein, L., Gold, L. S., Ames, B. N., et al. (1985). Some tautologous aspects of the comparison of carcinogenic potency in rats and mice. Fundam Appl Toxicol 5, 79-86.
48. Berwald, Y. and Sachs, L. (1963). In Vitro Cell Transformation with Chemical Carcinogens. Nature 200, 1182-1184.
49. Berwald, Y. and Sachs, L. (1965). In vitro transformation of normal cells to tumor cells by carcinogenic hydrocarbons. J Natl Cancer Inst 35, 641-661.
50. Bessems, M., t Hart, N. A., Tolba, R., et al. (2006). The isolated perfused rat liver: standardization of a time-honoured model. Lab Anim 40, 236-246.
51. Bhogal, N., Grindon, C., Combes, R., et al. (2005). Toxicity testing: creating a revolution based on new technologies. Trends Biotechnol 23, 299-307.
52. Bitsch, A., Jacobi, S., Melber, C., et al. (2006). REPDOSE: A database on repeated dose toxicity studies of commercial chemicals - A multifunctional tool. Regul Toxicol Pharmacol 46, 202-210.
53. Blaauboer, B. J. (2001). Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicol Lett 120, 111-123.
54. Blaauboer, B. J., Clewell, H. J., Clothier, R., et al. (2001). In vitro methods for assessing acute toxicity: biokinetic determinations. Report of the International Workshop on in vitro methods for assessing acute systemic toxicity. NIEHS. 01-4499. NIH, 47-60. http://www.epa.gov/hpv/pubs/general/ nih2001a.pdf
55. Blaauboer, B. J. (2002). The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern Lab Anim 30, Suppl 2, 85-91.
56. Blaauboer, B. J. (2003). The integration of data on physicochemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol Lett 138, 161-171.
57. Blaauboer, B. J. (2010). Biokinetic modeling and in vitro-in vivo extrapolations. J Toxicol Environ Health B Crit Rev 13, 242-252.
58. Blakey, D., Galloway, S. M., Kirkland, D. J., et al. (2008). Regulatory aspects of genotoxicity testing: from hazard identification to risk assessment. Mutat Res 657, 84-90.
59. Bobr, A., Olvera-Gomez, I., Igyarto, B. Z., et al. (2010). Acute ablation of Langerhans cells enhances skin immune responses. J Immunol 185, 4724-4728.
60. Boekelheide, K. and Andersen, M. E. (2010). A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. ALTEX 27, 243-252.
61. st century: using the new toxicity testing paradigm to create a taxonomy of adverse effects. Toxicol Sci 114, 20-24.
62. Boraso, M. and Viviani, B. (2011). Glia-neuron sandwich cocultures: an in vitro approach to evaluate cell-to-cell communication in neuroinflammation and neurotoxicity. Methods Mol Biol 758, 135-152.
63. Bottini, A. A. and Hartung, T. (2009). Food for thought ... on the economics of animal testing. ALTEX 26, 3-16.
64. Bottini, A. A. and Hartung, T. (2010). The economics of animal testing. ALTEX 67-77.
65. Bouvier d'Yvoire, M., Prieto, P., Blaauboer, B. J., et al. (2007). Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern Lab Anim 35, 661-671.
66. Breithaupt, H. (2006). The costs of REACH. REACH is largely welcomed, but the requirement to test existing chemicals for adverse effects is not good news for all. EMBO Rep 7, 968-971.
67. Bremer, S., Pellizzer, C., Coecke, S., et al. (2002). Detection of the embryotoxic potential of cyclophosphamide by using a combined system of metabolic competent cells and embryonic stem cells. Altern Lab Anim 30, 77-85.
68. Bremer, S. and Hartung, T. (2004). The use of embryonic stem cells for regulatory developmental toxicity testing in vitro - the current status of test development. Curr Pharm Des 10, 2733-2747.
69. Bremer, S., Brittebo, E., Dencker, L., et al. (2007a). In vitro tests for detecting chemicals affecting the embryo implantation process. The report and recommendations of ECVAM workshop 62 - a strategic workshop of the EU ReProTect project. Altern Lab Anim 35, 421-439.
70. Bremer, S., Pellizzer, C., Hoffmann, S., et al. (2007b). The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programmes. Curr Pharm Des 13, 3047-3058.
71. Bridges, B. A. (1988). Genetic toxicology at the crossroads - a personal view on the deployment of short-term tests for predicting carcinogenicity. Mutat Res 205, 25-31.
72. Brown, N. A. and Fabro, S. (1983). The value of animal teratogenicity testing for predicting human risk. Clin Obstet Gynecol 26, 467-477.
73. Brown, R. P., Delp, M. D., Lindstedt, S. L., et al. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13, 407-484.
74. Brunner, D., Frank, J., Appl, H., et al. (2010). Serum-free cell culture: the serum-free media interactive online database. ALTEX 27, 53-62.
75. Bucher, J. R. (1998). Update on national toxicology program (NTP) assays with genetically altered or "transgenic" mice. Environ Health Perspect 106, 619-621.
76. Bucher, J. R. (2000). Doses in rodent cancer studies: sorting fact from fiction. Drug Metab Rev 32, 153-163.
77. Buehler, E. V. (1965). Delayed Contact Hypersensitivity in the Guinea Pig. Arch Dermatol 91, 171-177.
78. Calabrese, E. J. (2009). The road to linearity: why linearity at low doses became the basis for carcinogen risk assessment. Arch Toxicol 83, 203-225.
79. Calabrese, E. J. (2011). Muller's Nobel lecture on dose-response for ionizing radiation: ideology or science? Arch Toxicol 85, 1495-1498.
80. Carfi, M., Gennari, A., Malerba, I., et al. (2007). In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 229, 11-22.
81. Carney, E. W. and Kimmel, C. A. (2007). Interpretation of skeletal variations for human risk assessment: delayed ossification and wavy ribs. Birth Defects Res B Dev Reprod Toxicol 80, 473-496.
82. Carney, E. W., Ellis, A. L., Tyl, R. W., et al. (2011). Critical evaluation of current developmental toxicity testing strategies: a case of babies and their bathwater. Birth Defects Res B Dev Reprod Toxicol 92, 395-403.
83. Chahoud, I., Buschmann, J., Clark, R., et al. (1999). Classification terms in developmental toxicology: need for harmonisation. Report of the Second Workshop on the Terminology in Developmental Toxicology Berlin, 27-28 August 1998. Reprod Toxicol 13, 77-82.
84. st century. Toxicol Sci 112, 17-22.
85. Chen, J. J., Moon, H., and Kodell, R. L. (2007). A probabilistic framework for non-cancer risk assessment. Regul Toxicol Pharmacol 48, 45-50.
86. Chiba, M., Ishii, Y., and Sugiyama, Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11, 262-276.
87. Choi, S. M., Yoo, S. D., and Lee, B. M. (2004). Toxicological characteristics of endocrine-disrupting chemicals: developmental toxicity, carcinogenicity, and mutagenicity. J Toxicol Environ Health B Crit Rev 7, 1-24.
88. Clausen, B. E. and Kel, J. M. (2010). Langerhans cells: critical regulators of skin immunity? Immunol Cell Biol 88, 351-360.
89. Clewell, H. J., 3rd (1993). Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol Lett 68, 101-117.
90. Coecke, S., Balls, M., Bowe, G., et al. (2005). Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice. Altern Lab Anim 33, 261-287.
91. Coecke, S., Ahr, H., Blaauboer, B. J., et al. (2006). Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern Lab Anim 34, 49-84.
92. Coecke, S., Goldberg, A. M., Allen, S., et al. (2007). Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ Health Perspect 115, 924-931.
93. Cohen, S. M., Robinson, D., and MacDonald, J. (2001). Alternative models for carcinogenicity testing. Toxicol Sci 64, 14-19.
94. Cohen, S. M. (2004). Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol Sci 80, 225-229.
95. Cohen, S. M. and Arnold, L. L. (2011). Chemical carcinogenesis. Toxicol Sci 120, Suppl 1, S76-92.
96. Colacci, A., Mascolo, M. G., Perdichizzi, S., et al. (2011). Different sensitivity of BALB/c 3T3 cell clones in the response to carcinogens. Toxicol In Vitro 25, 1183-1190.
97. Collins, F. S., Gray, G. M., and Bucher, J. R. (2008). Toxicology. Transforming environmental health protection. Science 319, 906-907.
98. Collins, T. F. (2006). History and evolution of reproductive and developmental toxicology guidelines. Curr Pharm Des 12, 1449-1465.
99. Combes, R., Balls, M., Curren, R., et al. (1999). Cell transformation assays as predictors of human carcinogenicity - the report of ECVAM workshop 39. Altern Lab Anim, 745-767.
100. Combes, R., Grindon, C., Cronin, M. T., et al. (2007). Proposed integrated decision-tree testing strategies for mutagenicity and carcinogenicity in relation to the EU REACH legislation. Altern Lab Anim 35, 267-287.
101. Corvi, R., Ahr, H. J., Albertini, S., et al. (2006). Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect 114, 420-429.
102. Cox, J. L. and Rizzino, A. (2010). Induced pluripotent stem cells: what lies beyond the paradigm shift. Exp Biol Med (Maywood) 235, 148-158.
103. Crebelli, R. (2000). Threshold-mediated mechanisms in mutagenesis: implications in the classification and regulation of chemical mutagens. Mutat Res 464, 129-135.
104. Creton, S., Aardema, M. J., Carmichael, P. L., et al. (2011). Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis
105. Crofton, K. M., Mundy, W. R., Lein, P. J., et al. (2011). Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals. ALTEX 28, 9-15.
106. Cronin, M. T., Dearden, J. C., Duffy, J. C. (2002). The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ. Res. 13, 167-76.
107. Cronin, M. T., Enoch, S. J., Hewitt, M., et al. (2011). Formation of mechanistic categories and local models to facilitate the prediction of toxicity. ALTEX 28, 45-49.
108. Crow, J. A., Borazjani, A., Potter, P. M., et al. (2007). Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol 221, 1-12.
109. Daneshian, M., Leist, M., and Hartung, T. (2010). The Center for Alternatives to Animal Testing - Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. ALTEX 27, 63-69.
110. Darnell, M., Schreiter, T., Zeilinger, K., et al. (2011). Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab Dispos 39, 1131-1138.
111. Dash, A., Inman, W., Hoffmaster, K., et al. (2009). Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 5, 1159-1174.
112. Daston, G. P. and Seed, J. (2007). Skeletal malformations and variations in developmental toxicity studies: interpretation issues for human risk assessment. Birth Defects Res B Dev Reprod Toxicol 80, 421-424.
113. Davies, T. and Monro, A. (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. Int J Toxicol 14, 90-107.
114. Davies, T. S., Lynch, B. S., Monro, A. M., et al. (2000). Rodent carcinogenicity tests need be no longer than 18 months: an analysis based on 210 chemicals in the IARC monographs. Food Chem Toxicol 38, 219-235.
115. Davila, J., Stedman, D., Engle, S., et al. (2008). Stem cell technology for embryotoxicity, cardiotoxicity, and hepatotoxicity evaluation. In S. Ekins and J. J. Xu (eds.), Drug Efficacy, Safety, and Biologics Discovery: Emerging Technologies and Tools. Hoboken, USA: John Wiley & Sons.
116. De Buck, S. S. and Mackie, C. E. (2007). Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 3, 865-878.
117. de Jong, E., Doedee, A. M., Reis-Fernandes, M. A., et al. (2011). Potency ranking of valproic acid analogues as to inhibition of cardiac differentiation of embryonic stem cells in comparison to their in vivo embryotoxicity. Reprod Toxicol 31, 375-382.
118. De Silva, O., Basketter, D. A., Barrat, M. D., et al. (1995). Alternative methods for skin sensitisation testing: the report and recommendations of ECVAM workshop 19. Altern Lab Anim, 683-705.
119. De Smedt, A., Steemans, M., De Boeck, M., et al. (2008). Optimisation of the cell cultivation methods in the embryonic stem cell test results in an increased differentiation potential of the cells into strong beating myocard cells. Toxicol In Vitro 22, 1789-1796.
120. DeJongh, J., Verhaar, H. J., and Hermens, J. L. (1997). A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 72, 17-25.
121. Dejongh, J., Forsby, A., Houston, J. B., et al. (1999). an integrated approach to the prediction of systemic toxicity using computer-based biokinetic models and biological in vitro test methods: Overview of a prevalidation study based on the ECITTS project. Toxicol In Vitro 13, 549-554.
122. Derelanko, M. J. and Hollinger, M. A. (2001). Handbook of Toxicology. Vol. 2. London: Informa Healthcare.
123. st century assessment of "Endocrine disruption". ALTEX 27, 264-278.
124. Doll, R. and Peto, R. (1981). The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66, 1191-1308.
125. dos Santos, G. G., Reinders, J., Ouwehand, K., et al. (2009). Progress on the development of human in vitro dendritic cell based assays for assessment of the sensitizing potential of a compound. Toxicol Appl Pharmacol 236, 372-382.
126. dos Santos, G. G., Spiekstra, S. W., Sampat-Sardjoepersad, S. C., et al. (2011). A potential in vitro epidermal equivalent assay to determine sensitizer potency. Toxicol In Vitro 25, 347-357.
127. Doweyko, A. M. (2004). 3D-QSAR illusions. J Comput Aided Mol Des 18, 587-596.
128. Duff, T., Carter, S., Feldman, G., et al. (2002). Transepithelial resistance and inulin permeability as endpoints in in vitro nephrotoxicity testing. Altern Lab Anim 30, Suppl 2, 53-59.
129. Durodie, B. (2003). The true cost of precautionary chemicals regulation. Risk Anal 23, 389-398.
130. ECHA (European Chemicals Agency) (2008). Guidance on information requirements and chemical safety assessment, Chapter R.7a: Endpoint specific guidance. 1-428. http://www.echa.europa.eu/documents/10162/17224/information- requirements-r7a-en.pdf
131. Elespuru, R. K., Agarwal, R., Atrakchi, A. H., et al. (2009). Current and future application of genetic toxicity assays: the role and value of in vitro mammalian assays. Toxicol Sci 109, 172-179.
132. Emmendoerffer, A., Hecht, M., Boeker, T., et al. (2000). Role of inflammation in chemical-induced lung cancer. Toxicol Lett 112-113, 185-191.
133. Emter, R., Ellis, G., and Natsch, A. (2010). Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol Appl Pharmacol 245, 281-290.
134. Ennever, F. K., Noonan, T. J., and Rosenkranz, H. S. (1987). The predictivity of animal bioassays and short-term genotoxicity tests for carcinogenicity and non-carcinogenicity to humans. Mutagenesis 2, 73-78.
135. Ennever, F. K. and Lave, L. B. (2003). Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity. Regul Toxicol Pharmacol 38, 52-57.
136. Entine, J. (2011). Scared to Death - How Chemophobia Threatens Public Health. Vol. New York: American Council on Science & Health.
137. EPA - U.S. Environmental Protection Agency (1988). Reference physiological parameters in pharmacokinetic modeling 600/6-88/004. http://nepis.epa.gov → Search: "600688004"
138. EPA - U.S. Environmental Protection Agency (2009). The U.S. Environmental Protection Agency's Strategic Plan for evaluating the toxicity of chemicals. 1-38. http://nepis.epa.gov → Search: "100K09001"
139. Esch, M. B., King, T. L., and Shuler, M. L. (2011). The role of body-on-a-chip devices in drug and toxicity studies. Annu Rev Biomed Eng 13, 55-72.
140. Esteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8, 286-298.
141. Fagerholm, U. (2007). Prediction of human pharmacokinetics - evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59, 803-828.
142. Falsig, J., Latta, M., and Leist, M. (2004a). Defined inflammatory states in astrocyte cultures: correlation with susceptibility towards CD95-driven apoptosis. J Neurochem 88, 181-193.
143. Falsig, J., Porzgen, P., Lotharius, J., et al. (2004b). Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol 173, 2762-2770.
144. Farmer, P. B. (2002). Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment ILSI/HESI research programme on alternative cancer models: results of Syrian hamster embryo cell transformation assay. International Life Sciences Institute/Health and Environmental Science Institute. Toxicol Pathol 30, 536-538.
145. Febriana, S. A., Jungbauer, F., Soebono, H., et al. (2011). Inventory of the chemicals and the exposure of the workers' skin to these at two leather factories in Indonesia. Int Arch Occup Environ Health
146. Felter, S., Lane, R. W., Latulippe, M. E., et al. (2009). Refining the threshold of toxicological concern (TTC) for risk prioritization of trace chemicals in food. Food Chem Toxicol 47, 2236-2245.
147. Fielden, M. R., Nie, A., McMillian, M., et al. (2008). Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol Sci 103, 28-34.
148. Fielden, M. R., Adai, A., Dunn, R. T., 2nd, et al. (2011). Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat. Toxicol Sci 124, 54-74.
149. Filser, J. G., Csanady, G. A., Kreuzer, P. E., et al. (1995). Toxicokinetic models for volatile industrial chemicals and reactive metabolites. Toxicol Lett 82-83, 357-366.
150. Fleischer, M. (2007). Testing costs and testing capacity according to the REACH requirements. Results of a survey of independent and corporate GLP laboratories in the EU and Switzerland. Journal of Business Chemistry 4, 96-114.
151. Forsby, A. and Blaauboer, B. (2007). Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Hum Exp Toxicol 26, 333-338.
152. Freedman, D. A. and Zeisel, H. (1988). From mouse to man: The quantitative assessment of cancer risks. Statist Sci 3-56.
153. Friedman, J. M. (2009). Big risks in small groups: The difference between epidemiology and counselling. Birth Defects Res A Clin Mol Teratol 85, 720-724.
154. Fung, V. A., Barrett, J. C., and Huff, J. (1995). The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. Environ Health Perspect 103, 680-683.
155. Galbiati, V., Mitjans, M., and Corsini, E. (2010). Present and future of in vitro immunotoxicology in drug development. J Immunotoxicol 7, 255-267.
156. Galbiati, V., Mitjans, M., Lucchi, L., et al. (2011). Further development of the NCTC 2544 IL-18 assay to identify in vitro contact allergens. Toxicol In Vitro 25, 724-732.
157. Gaylor, D. W. (2005). Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens? Regul Toxicol Pharmacol 41, 128-133.
158. Gennari, A., Ban, M., Braun, A., et al. (2005). The use of in vitro systems for evaluating immunotoxicity: The report and recommendations of an ECVAM Workshop. J Immunotoxicol 2, 61-83.
159. Genschow, E., Spielmann, H., Scholz, G., et al. (2002). The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern Lab Anim 30, 151-176.
160. Genschow, E., Spielmann, H., Scholz, G., et al. (2004). Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 209-244.
161. Georgiades, P., Ferguson-Smith, A. C., and Burton, G. J. (2002). Comparative developmental anatomy of the murine and human definitive placentae. Placenta 23, 3-19.
162. Gerberick, G. F., Vassallo, J. D., Bailey, R. E., et al. (2004). Development of a peptide reactivity assay for screening contact allergens. Toxicol Sci 81, 332-343.
163. Gerberick, G. F., Troutman, J. A., Foertsch, L. M., et al. (2009). Investigation of peptide reactivity of pro-hapten skin sensitizers using a peroxidase-peroxide oxidation system. Toxicol Sci 112, 164-174.
164. Gimble, J. and Guilak, F. (2003). Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. Cytotherapy 5, 362-369.
165. Gold, L. S., Slone, T. H., Manley, N. B., et al. (1991). Target organs in chronic bioassays of 533 chemical carcinogens. Environ Health Perspect 93, 233-246.
166. Gold, L. S., Slone, T. H., and Ames, B. N. (1998). What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database. Drug Metab Rev 30, 359-404.
167. Gold, L. S., Manley, N. B., Slone, T. H., et al. (2005). Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol Sci 85, 747-808.
168. Gomez-Lechon, M. J., Castell, J. V., and Donato, M. T. (2007). Hepatocytes - the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 168, 30-50.
169. Goodman, J. I., Gollapudi, B., and Lehman-McKeeman, L. D. (2007). Genetic toxicity assessment: employing the best science for human safety evaluation. Toxicol Sci 1, 1.
170. Gottmann, E., Kramer, S., Pfahringer, B., et al. (2001). Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. Environ Health Perspect 109, 509-514.
171. Gray, G. M., Li, P., Shlyakhter, I., et al. (1995). An empirical examination of factors influencing prediction of carcinogenic hazard across species. Regul Toxicol Pharmacol 22, 283-291.
172. Greenhough, S., Medine, C. N., and Hay, D. C. (2010). Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology 278, 250-255.
173. Greenland, S. (1998). Probability logic and probabilistic induction. Epidemiology 9, 322-332.
174. Griesinger, C., Hoffmann, S., Kinsner-Ovaskainen, A., et al. (2007). Proceedings of the First International Forum Towards Evidence-Based Toxicology. First International Forum Towards Evidence-Based Toxicology, Como, Italy. Human Exp. Toxicol 28, Spec. Issue, 83-176.
175. Grindon, C., Combes, R., Cronin, M. T., et al. (2008). An integrated decision-tree testing strategy for repeat dose toxicity with respect to the requirements of the EU REACH legislation. Altern Lab Anim 36, Suppl 1, 139-147.
176. Groebe, K., Hayess, K., Klemm-Manns, M., et al. (2010). Protein biomarkers for in vitro testing of embryotoxicity. J Proteome Res 9, 5727-5738.
177. Guguen-Guillouzoa, C., Corlua, A., Guillouzo, A. (2010) Stem cell-derived hepatocytes and their use in toxicology. Toxicology 270, 3-9.
178. Gulden, M. and Seibert, H. (1997). Influence of protein binding and lipophilicity on the distribution of chemical compounds in in vitro systems. Toxicol In Vitro 11, 479-483.
179. Gulden, M., Morchel, S., and Seibert, H. (2001). Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. Toxicol In Vitro 15, 233-243.
180. Gulden, M., Morchel, S., Tahan, S., et al. (2002). Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro. Toxicology 175, 201-213.
181. Gulden, M. and Seibert, H. (2003). In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. Toxicology 189, 211-222.
182. Gulden, M., Dierickx, P., and Seibert, H. (2006). Validation of a prediction model for estimating serum concentrations of chemicals which are equivalent to toxic concentrations in vitro. Toxicol In Vitro 20, 1114-1124.
183. Guyton, K. Z., Kyle, A. D., Aubrecht, J., et al. (2009). Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res 681, 230-240.
184. Hareng, L., Pellizzer, C., Bremer, S., et al. (2005). The integrated project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reprod Toxicol 20, 441-452.
185. Hartung, T., Bremer, S., Casati, S., et al. (2004). A modular approach to the ECVAM principles on test validity. Altern Lab Anim 32, 467-472.
186. Hartung, T. (2007a). Food for thought ... on cell culture. ALTEX 24, 143-152.
187. Hartung, T. (2007b). Food for thought ... on validation. ALTEX 24, 67-80.
188. Hartung, T. (2008a). Food for thought ... on alternative methods for cosmetics safety testing. ALTEX 25, 147-162.
189. Hartung, T. (2008b). Food for thought ... on animal tests. ALTEX 25, 3-16.
190. Hartung, T. (2008c). Toward a new toxicology - evolution or revolution? Altern Lab Anim 36, 635-639.
191. Hartung, T. and Leist, M. (2008). Food for thought ... on the evolution of toxicology and the phasing out of animal testing. ALTEX 25, 91-102.
192. Hartung, T. (2009a). Toxicology for the twenty-first century. Nature 460, 208-212.
193. Hartung, T. (2009b). Food for thought ... on evidence-based toxicology. ALTEX 26, 75-82.
194. Hartung, T. (2009c). Per aspirin ad astra. Altern Lab Anim 37, Suppl 2, 45-47.
195. Hartung, T. (2009d). A toxicology for the 21st century - mapping the road ahead. Toxicol Sci 109, 18-23.
196. Hartung, T. and Hoffmann, S. (2009). Food for thought ... on in silico methods in toxicology. ALTEX 26, 155-166.
197. Hartung, T. and Rovida, C. (2009a). Chemical regulators have overreached. Nature 460, 1080-1081.
198. Hartung, T. and Rovida, C. (2009b). That which must not, can not be... A reply to the EChA and EDF responses to the REACH analysis of animal use and costs. ALTEX 26, 307-311.
199. Hartung, T. (2010a). Food for thought ... on alternative methods for chemical safety testing. ALTEX 27, 3-14.
200. 1st century. J Toxicol Environ Health B Crit Rev 13, 277-290.
201. st century? ALTEX 27, 253-263.
202. 4 report. ALTEX 27, 285-303.
203. Hartung, T. (2010e). Food for thought ... on alternative methods for nanoparticle safety testing. ALTEX 27, 87-95.
204. Hartung, T., Bruner, L., Curren, R., et al. (2010). First alternative method validated by a retrospective weight-of-evidence approach to replace the Draize eye test for the identification of non-irritant substances for a defined applicability domain. ALTEX 27, 43-51.
205. Hartung, T. (2011). From alternative methods to a new toxicology. Eur J Pharm Biopharm 77, 338-349.
206. Hartung, T., Blaauboer, B. J., Bosgra, S., et al. (2011). An expert consortium review of the EC-commissioned report "alternative (Non-Animal) methods for cosmetics testing: current status and future prospects - 2010". ALTEX 28, 183-209.
207. Hartung, T. and McBride, M. (2011). Food for thought ... on mapping the human toxome. ALTEX 28, 83-93.
208. Hartung, T. and Sabbioni, E. (2011). Alternative in vitro assays in nanomaterial toxicology. Wiley Interdiscip Rev Nanomed Nanobiotechnol
209. Haseman, J., Melnick, R., Tomatis, L., et al. (2001). Carcinogenesis bioassays: study duration and biological relevance. Food Chem Toxicol 39, 739-744.
210. Haseman, J. K., Boorman, G. A., and Huff, J. (1997). Value of historical control data and other issues related to the evaluation of long-term rodent carcinogenicity studies. Toxicol Pathol 25, 524-527.
211. Hawkins, D. M. (2004). The problem of overfitting. J Chem Inf Comput Sci 44, 1-12.
212. Helma, C. and Kramer, S. (2003). A survey of the Predictive Toxicology Challenge 2000-2001. Bioinformatics 19, 1179-1182.
213. Henn, A., Lund, S., Hedtjarn, M., et al. (2009). The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26, 83-94.
214. Hestermann, E. V., Stegeman, J. J., and Hahn, M. E. (2000). Serum alters the uptake and relative potencies of halogenated aromatic hydrocarbons in cell culture bioassays. Toxicol Sci 53, 316-325.
215. Hettwer, M., Reis-Fernandes, M. A., Iken, M., et al. (2010). Metabolic activation capacity by primary hepatocytes expands the applicability of the embryonic stem cell test as alternative to experimental animal testing. Reprod Toxicol 30, 113-120.
216. Hoffmann, S. and Hartung, T. (2005). Diagnosis: toxic! - trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol Sci 85, 422-428.
217. Hoffmann, S. and Hartung, T. (2006). Toward an evidence-based toxicology. Hum Exp Toxicol 25, 497-513.
218. Hoffmann, S., Edler, L., Gardner, I., et al. (2008). Points of reference in the validation process: the report and recommendations of ECVAM Workshop 66. Altern Lab Anim 36, 343-352.
219. Hoke, R. A. and Ankley, G. T. (2005). Application of frog embryo teratogenesis assay-Xenopus to ecological risk assessment. Environ Toxicol Chem 24, 2677-2690.
220. Holson, J., Nemec, M., Stump, D. G., et al. (2006). Significance, reliability, and interpretation of developmental and reproductive toxicity study findings. In R. Hood (eds.), Developmental and Reproductive Toxicology. A Practical Approach. London, UK: Informa Healthcare.
221. Hotchkiss, A. K., Rider, C. V., Blystone, C. R., et al. (2008). Fifteen years after "Wingspread" - environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go. Toxicol Sci 105, 235-259.
222. Houston, J. B. and Carlile, D. J. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29, 891-922.
223. Houston, J. B. and Galetin, A. (2008). Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9, 940-951.
224. Huang, S., Wiszniewski, L., and Derouette, J. (2009). Disease Models: In vitro organ culture models of asthma. Drug Discovery Today 6, 137-144.
225. Huff, J. (1999). Long-term chemical carcinogenesis bioassays predict human cancer hazards. Issues, controversies, and uncertainties. Ann N Y Acad Sci 895, 56-79.
226. Hurtt, M. E., Cappon, G. D., and Browning, A. (2003). Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food-producing animals. Food Chem Toxicol 41, 611-619.
227. Imai, T., Imoto, M., Sakamoto, H., et al. (2005). Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos 33, 1185-1190.
228. Imai, T. (2006). Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21, 173-185.
229. th World Congress on Alternatives & Animal Use in the Life Sciences, Tokyo. AATEX 14, Spec. Issue, 457-462.
230. Jacobs, A. (2009). An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs. Toxicol Lett 186, 32-35.
231. Jaenisch, R. (2009). Stem cells, pluripotency and nuclear reprogramming. J Thromb Haemost 7, Suppl 1, 21-23.
232. Jager, T., Vermeire, T. G., Rikken, M. G., et al. (2001). Opportunities for a probabilistic risk assessment of chemicals in the European Union. Chemosphere 43, 257-264.
233. Jamei, M., Marciniak, S., Feng, K., et al. (2009). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5, 211-223.
234. Janer, G., Hakkert, B. C., Slob, W., et al. (2007). A retrospective analysis of the two-generation study: what is the added value of the second generation? Reprod Toxicol 24, 97-102.
235. th World Congress on Alternatives and Animal Use in the Life Sciences, Berlin. ALTEX 22, Spec. Issue, 132.
236. Jaworska, J., Gabbert, S., and Aldenberg, T. (2010). Towards optimization of chemical testing under REACH: a Bayesian network approach to Integrated Testing Strategies. Regul Toxicol Pharmacol 57, 157-167.
237. Jaworska, J. and Hoffmann, S. (2010). Integrated Testing Strategy (ITS) - Opportunities to better use existing data and guide future testing in toxicology. ALTEX 27, 231-242.
238. Jaworska, J., Harol, A., Kern, P. S., et al. (2011). Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. ALTEX 28, 211-225.
239. Jemal, A., Siegel, R., Ward, E., et al. (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
240. Jemal, A., Siegel, R., Xu, J., et al. (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
241. Jensen, J., Hyllner, J., and Bjorquist, P. (2009). Human embryonic stem cell technologies and drug discovery. J Cell Physiol 219, 513-519.
242. Johansson, H., Lindstedt, M., Albrekt, A. S., et al. (2011). A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics 12, 399.
243. Johnson, F. M. (1999). Carcinogenic chemical-response "fingerprint" for male F344 rats exposed to a series of 195 chemicals: implications for predicting carcinogens with transgenic models. Environ Mol Mutagen 34, 234-245.
244. Johnson, F. M. (2001). Response to Tennant et al.: Attempts to replace the NTP rodent bioassay with transgenic alternatives are unlikely to succeed. Environ Mol Mutagen 37, 89-92.
245. Johnson, F. M. and Huff, J. (2002). Bioassay bashing is bad science. Environ Health Perspect 110, A736-737; author reply A737-739.
246. Johnson, F. M. (2003). How many high production chemicals are rodent carcinogens? Why should we care? What do we need to do about it? Mutat Res 543, 201-215.
247. Jowsey, I. R., Basketter, D. A., Westmoreland, C., et al. (2006). A future approach to measuring relative skin sensitising potency: a proposal. J Appl Toxicol 26, 341-350.
248. Judson, R., Richard, A., Dix, D. J., et al. (2009). The toxicity data landscape for environmental chemicals. Environ Health Perspect 117, 685-695.
249. Judson, R. (2010). Public databases supporting computational toxicology. J Toxicol Environ Health B Crit Rev 13, 218-231.
250. Judson, R. S., Martin, M. T., Reif, D. M., et al. (2010). Analysis of eight oil spill dispersants using rapid, in vitro tests for endocrine and other biological activity. Environ Sci Technol 44, 5979-5985.
251. Judson, R. S., Kavlock, R. J., Setzer, R. W., et al. (2011). Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem Res Toxicol 24, 451-462.
252. Julien, E., Willhite, C. C., Richard, A. M., et al. (2004). Challenges in constructing statistically based structure-activity relationship models for developmental toxicity. Birth Defects Res A Clin Mol Teratol 70, 902-911.
253. Kaderali, L., Dazert, E., Zeuge, U., et al. (2009). Reconstructing signaling pathways from RNAi data using probabilistic Boolean threshold networks. Bioinformatics 25, 2229-2235.
254. Kaplan, D. H., Kissenpfennig, A., and Clausen, B. E. (2008). Insights into Langerhans cell function from Langerhans cell ablation models. Eur J Immunol 38, 2369-2376.
255. Kaplan, D. H. (2010). In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol 31, 446-451.
256. Karleta, V., Andrlik, I., Braunmuller, S., et al. (2010). Poloxamer 188 supplemented culture medium increases the vitality of Caco-2 cells after subcultivation and freeze/thaw cycles. ALTEX 27, 191-197.
257. Kavlock, R. and Dix, D. (2010). Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J Toxicol Environ Health B Crit Rev 13, 197-217.
258. Kedderis, G. L., Carfagna, M. A., Held, S. D., et al. (1993). Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharmacol 123, 274-282.
259. Kedderis, G. L. and Held, S. D. (1996). Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol 140, 124-130.
260. Kedderis, G. L. (1997). Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 107, 109-121.
261. Kim, J. H. and Scialli, A. R. (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol Sci 122, 1-6.
262. Kimber, I. and Dearman, R. J. (1991). Investigation of lymph node cell proliferation as a possible immunological correlate of contact sensitizing potential. Food Chem Toxicol 29, 125-129.
263. Kimber, I. and Basketter, D. A. (1997). Contact sensitization: a new approach to risk assessment. Hum Ecol Risk Assess 3, 385-395.
264. Kimber, I., Gerberick, G. F., and Basketter, D. A. (1999a). Thresholds in contact sensitization: theoretical and practical considerations. Food Chem Toxicol 37, 553-560.
265. Kimber, I., Pichowski, J. S., Basketter, D. A., et al. (1999b). Immune responses to contact allergens: novel approaches to hazard evaluation. Toxicol Lett 106, 237-246.
266. Kimber, I., Pichowski, J. S., Betts, C. J., et al. (2001). Alternative approaches to the identification and characterization of chemical allergens. Toxicol In Vitro 15, 307-312.
267. Kimber, I., Dearman, R. J., Basketter, D. A., et al. (2002). The local lymph node assay: past, present and future. Contact Dermatitis 47, 315-328.
268. Kimber, I., Cumberbatch, M., and Dearman, R. J. (2009). Langerhans cell migration: not necessarily always at the center of the skin sensitization universe. J Invest Dermatol 129, 1852-1853.
269. Kimber, I., Basketter, D. A., and Dearman, R. J. (2010). Chemical allergens - what are the issues? Toxicology 268, 139-142.
270. Kimber, I., Basketter, D. A., Gerberick, G. F., et al. (2011). Chemical allergy: translating biology into hazard characterization. Toxicol Sci 120, Suppl 1, S238-268.
271. Kinsner-Ovaskainen, A., Akkan, Z., Casati, S., et al. (2009). Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop. Altern Lab Anim 37, 437-444.
272. Kirkland, D., Aardema, M., Henderson, L., et al. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat Res 584, 1-256.
273. Kirkland, D., Pfuhler, S., Tweats, D., et al. (2007). How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop. Mutat Res 628, 31-55.
274. Kirkwood, T. B. (2008). A systematic look at an old problem. Nature 451, 644-647.
275. Kirsch-Volders, M., Aardema, M., and Elhajouji, A. (2000). Concepts of threshold in mutagenesis and carcinogenesis. Mutat Res 464, 3-11.
276. Kleinstreuer, N. C., Smith, A. M., West, P. R., et al. (2011). Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol 257, 111-121.
277. Klemm, M. and Schrattenholz, A. (2004). Neurotoxicity of active compounds - establishment of hESC-lines and proteomics technologies for human embryo- and neurotoxicity screening and biomarker identification. ALTEX 21, Suppl 3, 41-48.
278. Klemm, M., Groebe, K., Soskic, V., et al. (2008). (Stem cell-based in vitro models as alternative methods for toxicity and efficacy tests in animals). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 51, 1033-1038.
279. Kluwe, W. M. (1982). Overview of phthalate ester pharmacokinetics in mammalian species. Environ Health Perspect 45, 3-9.
280. Knight, A., Bailey, J., and Balcombe, J. (2006a). Animal carcinogenicity studies: 2. Obstacles to extrapolation of data to humans. Altern Lab Anim 34, 29-38.
281. Knight, A., Bailey, J., and Balcombe, J. (2006b). Animal carcinogenicity studies: 1. Poor human predictivity. Altern Lab Anim 34, 19-27.
282. Knight, A., Bailey, J., and Balcombe, J. (2006c). Animal carcinogenicity studies: implications for the REACH system. Altern Lab Anim 34, Suppl 1, 139-147.
283. Knight, A. W., Little, S., Houck, K., et al. (2009). Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Regul Toxicol Pharmacol 55, 188-199.
284. Knudsen, T. B., Martin, M. T., Kavlock, R. J., et al. (2009). Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod Toxicol 28, 209-219.
285. Knudsen, T. B., Kavlock, R. J., Daston, G. P., et al. (2011). Developmental toxicity testing for safety assessment: new approaches and technologies. Birth Defects Res B Dev Reprod Toxicol 92, 413-420.
286. Kodell, R. L., Chen, J. J., Delongchamp, R. R., et al. (2006). Hierarchical models for probabilistic dose-response assessment. Regul Toxicol Pharmacol 45, 265-272.
287. Kola, I. and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3, 711-715.
288. Krewski, D., Acosta, D., Jr., Andersen, M., et al. (2010). Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 13, 51-138.
289. Kroes, R., Renwick, A. G., Cheeseman, M., et al. (2004). Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem Toxicol 42, 65-83.
290. Kroes, R., Kleiner, J., and Renwick, A. (2005). The threshold of toxicological concern concept in risk assessment. Toxicol Sci 86, 226-230.
291. Kroes, R., Renwick, A. G., Feron, V., et al. (2007). Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. Food Chem Toxicol 45, 2533-2562.
292. Krtolica, A. and Giritharan, G. (2010). Use of human embryonic stem cell-based models for male reproductive toxicity screening. Syst Biol Reprod Med 56, 213-221.
293. Kuegler, P. B., Zimmer, B., Waldmann, T., et al. (2010). Markers of murine embryonic and neural stem cells, neurons and astrocytes: reference points for developmental neurotoxicity testing. ALTEX 27, 17-42.
294. Kusama, M., Toshimoto, K., Maeda, K., et al. (2010). In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38, 1362-1370.
295. Kusuhara, H. and Sugiyama, Y. (2009). In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24, 37-52.
296. Lan, S. F. and Starly, B. (2011). Alginate based 3D hydrogels as an in vitro co-culture model platform for the toxicity screening of new chemical entities. Toxicol Appl Pharmacol 256, 62-72.
297. Langezaal, I., Coecke, S., and Hartung, T. (2001). Whole blood cytokine response as a measure of immunotoxicity. Toxicol In Vitro 15, 313-318.
298. Langezaal, I., Hoffmann, S., Hartung, T., et al. (2002). Evaluation and prevalidation of an immunotoxicity test based on human whole-blood cytokine release. Altern Lab Anim 30, 581-595.
299. Lankveld, D. P., Van Loveren, H., Baken, K. A., et al. (2010). In vitro testing for direct immunotoxicity: state of the art. Methods Mol Biol 598, 401-423.
300. Lass, C., Merfort, I., and Martin, S. F. (2010). In vitro and in vivo analysis of pro- and anti-inflammatory effects of weak and strong contact allergens. Exp Dermatol 19, 1007-1013.
301. Latta, M., Kunstle, G., Leist, M., et al. (2000). Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 191, 1975-1985.
302. Lau, C., Andersen, M. E., Crawford-Brown, D. J., et al. (2000). Evaluation of biologically based dose-response modeling for developmental toxicity: a workshop report. Regul Toxicol Pharmacol 31, 190-199.
303. Lave, L. B., Ennever, F. K., Rosenkranz, H. S., et al. (1988). Information value of the rodent bioassay. Nature 336, 631-633.
304. Leist, M., Bremer, S., Brundin, P., et al. (2008a). The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy. ALTEX 25, 163-190.
305. Leist, M., Hartung, T., and Nicotera, P. (2008b). The dawning of a new age of toxicology. ALTEX 25, 103-114.
306. Leist, M., Efremova, L., and Karreman, C. (2010). Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27, 309-317.
307. Liao, K. H., Tan, Y. M., and Clewell, H. J., 3rd (2007). Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal 27, 1223-1236.
308. Liebsch, M., Grune, B., Seiler, A., et al. (2011). Alternatives to animal testing: current status and future perspectives. Arch Toxicol 85, 841-858.
309. Loeb, L. A. and Harris, C. C. (2008). Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res 68, 6863-6872.
310. Loizou, G. and Hogg, A. (2011). MEGen: A Physiologically Based Pharmacokinetic Model Generator. Front Pharmacol 2, 56.
311. th World Congress on Alternatives & Animal Use in the Life Sciences, Tokyo. AATEX 14, Spec. Issue, 553-559.
312. Lorge, E. (2009). Genetic Toxicology Testing and its Relevance to Human Risk and Safety Evaluation. In B. Ballantyne, T. C. Marrs and T. Syversen (eds.), General and Applied Toxicology. Hoboken: Wiley.
313. Lotharius, J., Falsig, J., van Beek, J., et al. (2005). Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 25, 6329-6342.
314. Luch, A. (2005). Nature and nurture - lessons from chemical carcinogenesis. Nat Rev Cancer 5, 113-125.
315. Luijten, M., Verhoef, A., Westerman, A., et al. (2008). Application of a metabolizing system as an adjunct to the rat whole embryo culture. Toxicol In Vitro 22, 1332-1336.
316. Luijten, M., van Beelen, V. A., Verhoef, A., et al. (2010). Transcriptomics analysis of retinoic acid embryotoxicity in rat postimplantation whole embryo culture. Reprod Toxicol 30, 333-340.
317. Lund, S., Porzgen, P., Mortensen, A. L., et al. (2005). Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J Neurochem 92, 1439-1451.
318. Lund, S., Christensen, K. V., Hedtjarn, M., et al. (2006). The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 180, 71-87.
319. Lutz, W. K. (2000). A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum Exp Toxicol 19, 566-568; discussion 571-562.
320. MacDonald, J. S. (2004). Human carcinogenic risk evaluation, part IV: assessment of human risk of cancer from chemical exposure using a global weight-of-evidence approach. Toxicol Sci 82, 3-8.
321. MacKeigan, J. P., Murphy, L. O., and Blenis, J. (2005). Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7, 591-600.
322. Magkoufopoulou, C., Claessen, S. M., Jennen, D. G., et al. (2011). Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis 26, 593-604.
323. Magnusson, B. and Kligman, A. M. (1969). The identification of contact allergens by animal assay. The guinea pig maximization test. J Invest Dermatol 52, 268-276.
324. Maguire, T. J., Novik, E., Chao, P., et al. (2009). Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr Drug Metab 10, 1192-1199.
325. Makris, S. L., Solomon, H. M., Clark, R., et al. (2009). Terminology of developmental abnormalities in common laboratory mammals (version 2). Reprod Toxicol 28, 371-434.
326. Makris, S. L., Kim, J. H., Ellis, A., et al. (2011). Current and future needs for developmental toxicity testing. Birth Defects Res B Dev Reprod Toxicol 92, 384-394.
327. Martin, M. T., Judson, R. S., Reif, D. M., et al. (2009a). Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef Database. Environ Health Perspect 117, 392-399.
328. Martin, M. T., Mendez, E., Corum, D. G., et al. (2009b). Profiling the reproductive toxicity of chemicals from multigeneration studies in the toxicity reference database. Toxicol Sci 110, 181-190.
329. Martin, S. F., Dudda, J. C., Bachtanian, E., et al. (2008). Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med 205, 2151-2162.
330. Martin, S. F. and Jakob, T. (2008). From innate to adaptive immune responses in contact hypersensitivity. Curr Opin Allergy Clin Immunol 8, 289-293.
331. Martin, S. F., Esser, P. R., Schmucker, S., et al. (2010). T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cell Mol Life Sci 67, 4171-4184.
332. Martin, S. F., Esser, P. R., Weber, F. C., et al. (2011). Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 66, 1152-1163.
333. Mascolo, M. G., Perdichizzi, S., Rotondo, F., et al. (2010). BALB/c 3T3 cell transformation assay for the prediction of carcinogenic potential of chemicals and environmental mixtures. Toxicol In Vitro 24, 1292-1300.
334. Matthews, E. J., Kruhlak, N. L., Cimino, M. C., et al. (2006). An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul Toxicol Pharmacol 44, 97-110.
335. Matthews, E. J., Kruhlak, N. L., Daniel Benz, R., et al. (2007). A comprehensive model for reproductive and developmental toxicity hazard identification: II. Construction of QSAR models to predict activities of untested chemicals. Regul Toxicol Pharmacol 47, 136-155.
336. Mattison, D. R. (2010). Environmental exposures and development. Curr Opin Pediatr 22, 208-218.
337. Maxwell, G. and Mackay, C. (2008). Application of a systems biology approach to skin allergy risk assessment. Altern Lab Anim 36, 521-556.
338. Maxwell, G., Aeby, P., Ashikaga, T., et al. (2011). Skin sensitisation: the Colipa strategy for developing and evaluating non-animal test methods for risk assessment. ALTEX 28, 50-55.
339. Mazur, C. S., Kenneke, J. F., Hess-Wilson, J. K., et al. (2010). Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38, 2232-2238.
340. Mazzotti, F., Sabbioni, E., Ponti, J., et al. (2002). In vitro setting of dose-effect relationships of 32 metal compounds in the Balb/3T3 cell line, as a basis for predicting their carcinogenic potential. Altern Lab Anim 30, 209-217.
341. McKim, J. M., Jr. (2010). Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance. Comb Chem High Throughput Screen 13, 188-206.
342. McKim, J. M., Jr., Keller, D. J., 3rd, and Gorski, J. R. (2010). A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol 29, 171-192.
343. McNeish, J. (2004). Embryonic stem cells in drug discovery. Nat Rev Drug Discov 3, 70-80.
344. McNeish, J. D. (2007). Stem cells as screening tools in drug discovery. Curr Opin Pharmacol 7, 515-520.
345. Mendel, C. M. (1992). The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl 13, 107-116.
346. Meng, Q. (2010). Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 6, 733-746.
347. Miranda, J. P., Leite, S. B., Muller-Vieira, U., et al. (2009). Towards an extended functional hepatocyte in vitro culture. Tissue Eng Part C Methods 15, 157-167.
348. Moffat, J. and Sabatini, D. M. (2006). Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol 7, 177-187.
349. Morelli, M. A. (2000). Industry viewpoint on thresholds for genotoxic carcinogens. Toxicol Pathol 28, 396-404.
350. Mose, T. and Knudsen, L. E. (2006). Placental perfusion - a human alternative. ALTEX 23, Suppl, 358-363.
351. Munro, I. C., Renwick, A. G., and Danielewska-Nikiel, B. (2008). The Threshold of Toxicological Concern (TTC) in risk assessment. Toxicol Lett 180, 151-156.
352. Myren, M., Mose, T., Mathiesen, L., et al. (2007). The human placenta - an alternative for studying foetal exposure. Toxicol In Vitro 21, 1332-1340.
353. Nakamura, K., Mizutani, R., Sanbe, A., et al. (2011). Evaluation of drug toxicity with hepatocytes cultured in a micro-space cell culture system. J Biosci Bioeng 111, 78-84.
354. Nassim, N. T. (2010). The Black Swan: The Impact of the Highly Improbable. Vol. 2. New York, USA: Random House Trade Paperbacks.
355. Natsch, A., Emter, R., and Ellis, G. (2009). Filling the concept with data: integrating data from different in vitro and in silico assays on skin sensitizers to explore the battery approach for animal-free skin sensitization testing. Toxicol Sci 107, 106-121.
356. Neumann, H. G. (2009). Risk assessment of chemical carcinogens and thresholds. Crit Rev Toxicol 39, 449-461.
357. Noordegraaf, M., Flacher, V., Stoitzner, P., et al. (2010). Functional redundancy of Langerhans cells and Langerin+ dermal dendritic cells in contact hypersensitivity. J Invest Dermatol 130, 2752-2759.
358. NRC (2007). Toxicity Testing in the Twenty-first Century: A Vision and a Strategy. Washington DC, USA: National Academies Press. http://www.nap.edu/ catalog.php?record-id=11970
359. O'Brien, J., Renwick, A. G., Constable, A., et al. (2006). Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. Food Chem Toxicol 44, 1613-1635.
360. OECD (1987). Acute Oral Toxicity. OECD Guideline for Testing of Chemical, TG No. 401. http://iccvam.niehs.nih.gov/docs/acutetox-docs/udpProc/udpfin01/ append/AppI.pdf
361. OECD (2001). Prenatal Developmental Toxicity Study. OECD Guidelines for Chemical Testing, TG No. 414. http://www.oecd.org/dataoecd/18/15/1948482.pdf
362. OECD (2004). Skin Absorption: in vitro Method. OECD Guidelines for Chemical Testing, TG No. 428. http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/ OECDtg428.pdf
363. OECD (2007). Detailed review paper on cell transformation assays for detection of chemical carcinogens. Series on Testing and Assessment No. 31. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/ MONO%282007%2918&docLanguage=En
364. OECD (2009). Carcinogenicity Studies. OECD Guidelines for Chemical Testing, TG No. 451. http://www.oecd.org/dataoecd/30/46/41753121.pdf
365. OECD (2011). Extended one-generation reproductive toxicity study .OECD Guidelines for Chemical Testing, TG No. 443. http://www.oecd-ilibrary.org → Search: "Extended one-generation reproductive toxicity study"
366. Ohshima, H., Tatemichi, M., and Sawa, T. (2003). Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417, 3-11.
367. Oliveira, P. A., Colaco, A., Chaves, R., et al. (2007). Chemical carcinogenesis. An Acad Bras Cienc 79, 593-616.
368. Olson, H., Betton, G., Robinson, D., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56-67.
369. Ouwehand, K., Spiekstra, S. W., Reinders, J., et al. (2010). Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells. Toxicol In Vitro 24, 578-585.
370. Paine, M. F., Khalighi, M., Fisher, J. M., et al. (1997). Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283, 1552-1562.
371. Pal, R., Mamidi, M. K., Das, A. K., et al. (2011). Human embryonic stem cell proliferation and differentiation as parameters to evaluate developmental toxicity. J Cell Physiol 226, 1583-1595.
372. Paterson, S. and Mackay, D. (1989). Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. Br J Ind Med 46, 321-328.
373. Patlewicz, G., Rodford, R., and Walker, J. D. (2003). Quantitative structure-activity relationships for predicting mutagenicity and carcinogenicity. Environ Toxicol Chem 22, 1885-1893.
374. Patlewicz, G., Aptula, A. O., Uriarte, E., et al. (2007). An evaluation of selected global (Q)SARs/expert systems for the prediction of skin sensitisation potential. SAR QSAR Environ Res 18, 515-541.
375. Pelkonen, O. and Turpeinen, M. (2007). In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37, 1066-1089.
376. Pelkonen, O., Kapitulnik, J., Gundert-Remy, U., et al. (2008). Local kinetics and dynamics of xenobiotics. Crit Rev Toxicol 38, 697-720.
377. Pelkonen, O., Tolonen, A., Korjamo, T., et al. (2009). From known knowns to known unknowns: predicting in vivo drug metabolites. Bioanalysis 1, 393-414.
378. Pellizzer, C., Adler, S., Corvi, R., et al. (2004). Monitoring of teratogenic effects in vitro by analysing a selected gene expression pattern. Toxicol In Vitro 18, 325-335.
379. Pellizzer, C., Bremer, S., and Hartung, T. (2005). Developmental toxicity testing from animal towards embryonic stem cells. ALTEX 22, 47-57.
380. Pepe, M. S. (2004). The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford, UK: Oxford Univ Pr.
381. Pessina, A., Albella, B., Bueren, J., et al. (2001). Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 15, 729-740.
382. Peyret, T. and Krishnan, K. (2011). QSARs for PBPK modelling of environmental contaminants. SAR QSAR Environ Res 22, 129-169.
383. Pfuhler, S., Kirkland, D., Kasper, P., et al. (2009). Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities-Report from an ECVAM workshop. Mutat Res 680, 31-42.
384. Pfuhler, S., Carmichael, P., Fowler, P., et al. (2010a). Animal-free genotoxicity testing: The COLIPA program. Toxicology Letters S248.
385. Pfuhler, S., Kirst, A., Aardema, M., et al. (2010b). A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: genotoxicity. A COLIPA analysis. Regul Toxicol Pharmacol 57, 315-324.
386. Piersma, A. H., Genschow, E., Verhoef, A., et al. (2004). Validation of the postimplantation rat whole-embryo culture test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 275-307.
387. Piersma, A. H., Janer, G., Wolterink, G., et al. (2008). Quantitative extrapolation of in vitro whole embryo culture embryotoxicity data to developmental toxicity in vivo using the benchmark dose approach. Toxicol Sci 101, 91-100.
388. Piersma, A. H., Hernandez, L. G., van Benthem, J., et al. (2011). Reproductive toxicants have a threshold of adversity. Crit Rev Toxicol 41, 545-554.
389. Plant, N. (2008). Can systems toxicology identify common biomarkers of non-genotoxic carcinogenesis? Toxicology 254, 164-169.
390. Ponti, J., Munaro, B., Fischbach, M., et al. (2007). An optimised data analysis for the Balb/c 3T3 cell transformation assay and its application to metal compounds. Int J Immunopathol Pharmacol 20, 673-684.
391. Poulin, P. and Krishnan, K. (1995). An algorithm for predicting tissue: blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. J Toxicol Environ Health 46, 117-129.
392. Poulsen, M. S., Rytting, E., Mose, T., et al. (2009). Modeling placental transport: correlation of in vitro BeWo cell permeability and ex vivo human placental perfusion. Toxicol In Vitro 23, 1380-1386.
393. Pratt, I., Barlow, S., Kleiner, J., et al. (2009). The influence of thresholds on the risk assessment of carcinogens in food. Mutat Res 678, 113-117.
394. Pritchard, J. B., French, J. E., Davis, B. J., et al. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111, 444-454.
395. Prusakiewicz, J. J., Ackermann, C., and Voorman, R. (2006). Comparison of skin esterase activities from different species. Pharm Res 23, 1517-1524.
396. Punt, A., Freidig, A. P., Delatour, T., et al. (2008). A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicol Appl Pharmacol 231, 248-259.
397. Punt, A., Paini, A., Boersma, M. G., et al. (2009). Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol Sci 110, 255-269.
398. Python, F., Goebel, C., and Aeby, P. (2007). Assessment of the U937 cell line for the detection of contact allergens. Toxicol Appl Pharmacol 220, 113-124.
399. Rall, D. P. (2000). Laboratory animal tests and human cancer. Drug Metab Rev 32, 119-128.
400. Raunio, H. (2011). In silico toxicology - non-testing methods. Front Pharmacol 2, 33.
401. Reuben, S. (2010). Reducing Environmental Cancer Risk: What We Can Do Now: 2008-2009 Annual Report, President's Cancer Panel. National Cancer Institute. NIH, 1-240. http://deainfo.nci.nih.gov/advisory/pcp/annualReports/ pcp08-09rpt/PCP-Report-08-09-508.pdf
402. Reuter, H., Spieker, J., Gerlach, S., et al. (2011). In vitro detection of contact allergens: development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells. Toxicol In Vitro 25, 315-323.
403. th Annual Meeting, Washington, DC.
404. Richert, L., Abadie, C., Bonet, A., et al. (2010). Inter-laboratory evaluation of the response of primary human hepatocyte cultures to model CYP inducers - a European Centre for Validation of Alternative Methods (ECVAM) - funded pre-validation study. Toxicol In Vitro 24, 335-345.
405. Rostami-Hodjegan, A. and Tucker, G. T. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6, 140-148.
406. Rotroff, D. M., Wetmore, B. A., Dix, D. J., et al. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 117, 348-358.
407. 4). ALTEX 26, 187-208.
408. Rovida, C. (2010). Food for thought ... why no new in vitro tests will be done for REACH by registrants. ALTEX 27, 175-183.
409. Rovida, C. (2011). Local lymph node assay: how testing laboratories apply OECD TG 429 for REACH purposes. ALTEX 28, 117-129.
410. Rovida, C., Longo, F., and Rabbit, R. R. (2011). How are reproductive toxicity and developmental toxicity addressed in REACH dossiers? ALTEX 28, 273-294.
411. Rule, A. D., Gussak, H. M., Pond, G. R., et al. (2004). Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis 43, 112-119.
412. Ryan, C. A., Gerberick, G. F., Gildea, L. A., et al. (2005). Interactions of contact allergens with dendritic cells: opportunities and challenges for the development of novel approaches to hazard assessment. Toxicol Sci 88, 4-11.
413. Sakaguchi, H., Ashikaga, T., Miyazawa, M., et al. (2006). Development of an in vitro skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT). II. An inter-laboratory study of the h-CLAT. Toxicol In Vitro 20, 774-784.
414. Sakai, A., Sasaki, K., Hayashi, K., et al. (2011). An international validation study of a Bhas 42 cell transformation assay for the prediction of chemical carcinogenicity. Mutat Res 725, 57-77.
415. Salsburg, D. (1983). The lifetime feeding study in mice and rats - an examination of its validity as a bioassay for human carcinogens. Fundam Appl Toxicol 3, 63-67.
416. Sambuy, Y., De Angelis, I., Ranaldi, G., et al. (2005). The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21, 1-26.
417. Schaafsma, G., Kroese, E. D., Tielemans, E. L., et al. (2009). REACH, non-testing approaches and the urgent need for a change in mind set. Regul Toxicol Pharmacol 53, 70-80.
418. Schardein, J. (2000). Chemically Induced Birth Defects. Vol. 3. London, UK: Informa Healthcare.
419. Scharf, J., Ramadori, G., Braulke, T., et al. (1996). Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology 23, 818-827.
420. Schmidt, C. W. (2002). Assessing assays. Environ Health Perspect 110, A248-251.
421. Schmidt, M., Raghavan, B., Muller, V., et al. (2010). Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 11, 814-819.
422. Schneider, K., Schwarz, M., Burkholder, I., et al. (2009). "ToxR-Tool", a new tool to assess the reliability of toxicological data. Toxicol Lett 189, 138-144.
423. Scholz, D., Poltl, D., Genewsky, A., et al. (2011). Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119, 957-971.
424. Scialli, A. R. (2008). The challenge of reproductive and developmental toxicology under REACH. Regul Toxicol Pharmacol 51, 244-250.
425. Seagle, C., Christie, M. A., Winnike, J. H., et al. (2008). High-throughput nuclear magnetic resonance metabolomic footprinting for tissue engineering. Tissue Eng Part C Methods 14, 107-118.
426. Seibert, H., Morchel, S., and Gulden, M. (2002). Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicol In Vitro 16, 289-297.
427. Seidle, T. (2006). Chemicals and Cancer: What the Regulators Won't Tell You. PETA Europe Ltd. http://www.peta.nl/pdf/PetaCancerReport.pdf
428. Seidle, T., Prieto, P., and Bulgheroni, A. (2011). Examining the regulatory value of multi-route mammalian acute systemic toxicity studies. ALTEX 28, 95-102.
429. Seiler, A., Visan, A., Buesen, R., et al. (2004). Improvement of an in vitro stem cell assay for developmental toxicity: the use of molecular endpoints in the embryonic stem cell test. Reprod Toxicol 18, 231-240.
430. Seiler, A. E. and Spielmann, H. (2011). The validated embryonic stem cell test to predict embryotoxicity in vitro. Nat Protoc 6, 961-978.
431. Selderslaghs, I. W., Blust, R., and Witters, H. E. (2011). Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. Reprod Toxicol
432. Shanks, N., Greek, R., and Greek, J. (2009). Are animal models predictive for humans? Philos Ethics Humanit Med 4, 2.
433. Silbergeld, E. K. (2004). Commentary: the role of toxicology in prevention and precaution. Int J Occup Med Environ Health 17, 91-102.
434. Silva Lima, B. and Van der Laan, J. W. (2000). Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regul Toxicol Pharmacol 32, 135-143.
435. Sipes, N. S., Martin, M. T., Reif, D. M., et al. (2011a). Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol Sci 124, 109-127.
436. Sipes, N. S., Padilla, S., and Knudsen, T. B. (2011b). Zebrafish: as an integrative model for twenty-first century toxicity testing. Birth Defects Res C Embryo Today 93, 256-267.
437. Skelin, M., Rupnik, M., and Cencic, A. (2010). Pancreatic beta cell lines and their applications in diabetes mellitus research. ALTEX 27, 105-113.
438. Snyder, R. D. and Green, J. W. (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488, 151-169.
439. Sobels, F. H. (1987). Environmental mutagenesis in retrospect. Mutat Res 181, 299-310.
440. Speit, G. (2009). How to assess the mutagenic potential of cosmetic products without animal tests? Mutat Res 678, 108-112.
441. Spielmann, H. and Gerbracht, U. (2001). The use of dogs as second species in regulatory testing of pesticides. Part II: Subacute, subchronic and chronic studies in the dog. Arch Toxicol 75, 1-21.
442. Spielmann, H., Genschow, E., Brown, N. A., et al. (2004). Validation of the rat limb bud micromass test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern Lab Anim 32, 245-274.
443. Spielmann, H., Seiler, A., Bremer, S., et al. (2006). The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern Lab Anim 34, 527-538.
444. Spielmann, H. (2010). The EU Commission's Draft Report on Alternative (Non-animal) Methods for Cosmetics Testing: Current Status and Future Prospects - 2010: a missed opportunity. Altern Lab Anim 38, 339-343.
445. Stokes, W. S. and Wind, M. (2010). Validation of innovative technologies and strategies for regulatory safety assessment methods: challenges and opportunities. ALTEX 27, 87-95.
446. Storm, J. E., Collier, S. W., Stewart, R. F., et al. (1990). Metabolism of xenobiotics during percutaneous penetration: role of absorption rate and cutaneous enzyme activity. Fundam Appl Toxicol 15, 132-141.
447. Sukardi, H., Chng, H. T., Chan, E. C., et al. (2011). Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models. Expert Opin Drug Metab Toxicol 7, 579-589.
448. Sung, J. H., Esch, M. B., and Shuler, M. L. (2010). Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Expert Opin Drug Metab Toxicol 6, 1063-1081.
449. Takahashi, K. and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
450. Takahashi, K., Tanabe, K., Ohnuki, M., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872.
451. Takayama, S., Thorgeirsson, U. P., and Adamson, R. H. (2008). Chemical carcinogenesis studies in nonhuman primates. Proc Jpn Acad Ser B Phys Biol Sci 84, 176-188.
452. Taylor, K., Casalegno, C., and Stengel, W. (2011). A critique of the EC's expert (draft) reports on the status of alternatives for cosmetics testing to meet the 2013 deadline. ALTEX 28, 131-148.
453. Teeguarden, J. G. and Barton, H. A. (2004). Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds. Risk Anal 24, 751-770.
454. Thilly, W. G. (2003). Have environmental mutagens caused oncomutations in people? Nat Genet 34, 255-259.
455. Toh, Y. C., Lim, T. C., Tai, D., et al. (2009). A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9, 2026-2035.
456. Toivonen, H., Srinivasan, A., King, R. D., et al. (2003). Statistical evaluation of the Predictive Toxicology Challenge 2000-2001. Bioinformatics 19, 1183-1193.
457. Toth, B. (2002). Species susceptibilities to chemical carcinogens: a critical appraisal of the roles of sex hormones (endocrine status) and nutritional influences. In Vivo 16, 161-166.
458. Troutman, J. A., Foertsch, L. M., Kern, P. S., et al. (2011). The incorporation of lysine into the peroxidase peptide reactivity assay for skin sensitization assessments. Toxicol Sci 122, 422-436.
459. Tukov, F. F., Maddox, J. F., Amacher, D. E., et al. (2006). Modeling inflammation-drug interactions in vitro: a rat Kupffer cell-hepatocyte coculture system. Toxicol In Vitro 20, 1488-1499.
460. Tweats, D. J., Scott, A. D., Westmoreland, C., et al. (2007). Determination of genetic toxicity and potential carcinogenicity in vitro - challenges post the Seventh Amendment to the European Cosmetics Directive. Mutagenesis 22, 5-13.
461. Uibel, F., Muhleisen, A., Kohle, C., et al. (2010). ReProGlo: a new stem cell-based reporter assay aimed to predict embryotoxic potential of drugs and chemicals. Reprod Toxicol 30, 103-112.
462. van Dartel, D. A. and Piersma, A. H. (2011). The embryonic stem cell test combined with toxicogenomics as an alternative testing model for the assessment of developmental toxicity. Reprod Toxicol 32, 235-244.
463. van de Kerkhof, E. G., de Graaf, I. A., and Groothuis, G. M. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab 8, 658-675.
464. van der Jagt, K., Munn, S., Torslov, J., et al. (2004). Alternative approaches can reduce the use of test animals under REACH. Addendum to the report "Assessment of additional testing needs under REACH. Effects of (Q)SARs, risk based testing and voluntary industry initiatives". European Commission. Joint Research Centre. 1-31. http://publications.jrc.ec.europa.eu/ repository/bitstream/111111111/8790/1/EUR%2021405%20EN.pdf
465. van der Voet, H. and Slob, W. (2007). Integration of probabilistic exposure assessment and probabilistic hazard characterization. Risk Anal 27, 351-371.
466. van Kesteren, P. C., Zwart, P. E., Pennings, J. L., et al. (2011). Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa-/-p53+/- mice upon exposure to benzo[a]pyrene. Toxicol Sci 123, 123-132.
467. van Leeuwen, C. J., Patlewicz, G. Y., and Worth, A. P. (2007). Intelligent Testing Strategies, in Risk Assessment of Chemicals. In C. J. van Leeuwen and T. G. Vermeire (eds.), Risk Assessment of Chemicals. An Introduction. Heidelberg, Germany: Springer.
468. van Leeuwen, I. M. and Zonneveld, C. (2001). From exposure to effect: a comparison of modeling approaches to chemical carcinogenesis. Mutat Res 489, 17-45.
469. Van Oosterhout, J. P., Van der Laan, J. W., De Waal, E. J., et al. (1997). The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul Toxicol Pharmacol 25, 6-17.
470. van Ravenzwaay, B. (2010). Initiatives to decrease redundancy in animal testing of pesticides. ALTEX 27, 159-161.
471. van Ravenzwaay, B., Dammann, M., Buesen, R., et al. (2011). The threshold of toxicological concern for prenatal developmental toxicity. Regul Toxicol Pharmacol 59, 81-90.
472. st century. ALTEX 28, 17-44.
473. Vandebriel, R. J. and van Loveren, H. (2010). Non-animal sensitization testing: state-of-the-art. Crit Rev Toxicol 40, 389-404.
474. Vanhaecke, T., Pauwels, M., Vinken, M., et al. (2011). Towards an integrated in vitro strategy for repeated dose toxicity testing. Arch Toxicol 85, 365-366.
475. Vanparys, P., Corvi, R., Aardema, M., et al. (2011). ECVAM prevalidation of three cell transformation assays. ALTEX 28, 56-59.
476. Verdonck, F. A., Van Sprang, P. A., and Vanrolleghem, P. A. (2005). Uncertainty and precaution in European environmental risk assessment of chemicals. Water Sci Technol 52, 227-234.
477. Verwei, M., van Burgsteden, J. A., Krul, C. A., et al. (2006). Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol Lett 165, 79-87.
478. Vinken, M., Doktorova, T., Ellinger-Ziegelbauer, H., et al. (2008). The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutat Res 659, 202-210.
479. Virshup, D. M. and Shenolikar, S. (2009). From promiscuity to precision: protein phosphatases get a makeover. Mol Cell 33, 537-545.
480. Viviani, B. (2006). Preparation and coculture of neurons and glial cells. Curr Protoc Cell Biol Chapter 2, Unit 2 7.
481. Volbracht, C., Leist, M., and Nicotera, P. (1999). ATP controls neuronal apoptosis triggered by microtubule breakdown or potassium deprivation. Mol Med 5, 477-489.
482. Volz, A., Piper, H. M., Siegmund, B., et al. (1991). Longevity of adult ventricular rat heart muscle cells in serum-free primary culture. J Mol Cell Cardiol 23, 161-173.
483. Ward, J. M. (2007). The two-year rodent carcinogenesis bioassay - Will it survive? J Toxicol Pathol 1, 13.
484. Waters, M. D., Jackson, M., and Lea, I. (2010). Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat Res 705, 184-200.
485. Weber, F. C., Esser, P. R., Muller, T., et al. (2010). Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med 207, 2609-2619.
486. Weigt, S., Huebler, N., Braunbeck, T., et al. (2010). Zebrafish teratogenicity test with metabolic activation (mDarT): effects of phase I activation of acetaminophen on zebrafish Danio rerio embryos. Toxicology 275, 36-49.
487. Weigt, S., Huebler, N., Strecker, R., et al. (2011). Zebrafish (Danio rerio) embryos as a model for testing proteratogens. Toxicology 281, 25-36.
488. West, P. R., Weir, A. M., Smith, A. M., et al. (2010). Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol 247, 18-27.
489. Westmoreland, C., Carmichael, P., Dent, M., et al. (2010). Assuring safety without animal testing: Unilever's ongoing research programme to deliver novel ways to assure consumer safety. ALTEX 27, 61-65.
490. Wetmore, B. A., Wambaugh, J. F., Ferguson, S. S., et al. (2011). Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 125, 157-174.
491. Widschwendter, M. and Jones, P. A. (2002). DNA methylation and breast carcinogenesis. Oncogene 21, 5462-5482.
492. Wilcox, N. and Goldberg, A. (2011). Food for thought ... on validation. A puzzle or a mystery: an approach founded on new science. ALTEX 28, 3-8.
493. Wilkinson, G. R. and Schenker, S. (1975). Drug disposition and liver disease. Drug Metab Rev 4, 139-175.
494. Williams, G. M. (2001). Mechanisms of chemical carcinogenesis and application to human cancer risk assessment. Toxicology 166, 3-10.
495. Wise, L. D., Beck, S. L., Beltrame, D., et al. (1997). Terminology of developmental abnormalities in common laboratory mammals (version 1). Teratology 55, 249-292.
496. Wogan, G. N., Hecht, S. S., Felton, J. S., et al. (2004). Environmental and chemical carcinogenesis. Semin Cancer Biol 14, 473-486.
497. Woodcock, J. and Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59, 1-12.
498. Woosley, R. L. and Cossman, J. (2007). Drug development and the FDA's Critical Path Initiative. Clin Pharmacol Ther 81, 129-133.
499. Yang, C. H., Glover, K. P., and Han, X. (2010). Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol Sci 117, 294-302.
500. Yang, J., Jamei, M., Yeo, K. R., et al. (2007). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8, 676-684.
501. Yang, L., Ho, N. Y., Alshut, R., et al. (2009). Zebrafish embryos as models for embryotoxic and teratological effects of chemicals. Reprod Toxicol 28, 245-253.
502. Zimmer, B., Schildknecht, S., Kuegler, P. B., et al. (2011). Sensitivity of dopaminergic neuron differentiation from stem cells to chronic low-dose methylmercury exposure. Toxicol Sci 121, 357-367.